UNSPSC 51172154: Vetrabutine or vetrabutine hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C20H27NO2 and C20H27NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers I3E2J32F37 and 54IF66RP20, the base comppound being chemically known as 1-(3,4-dimethoxyphenyl)-1-dimethylamino-4-phenylbutane but generally known as vetrabutine, which bears US NIH Compound Identifier 111122. European Medicines Agency schedules Vetrabutine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB00046MIG and SUB05093MIG.

UNSPSC 51172154 Vetrabutine or vetrabutine hydrochloride is a Commodity code nominally covering a specific pharmaceutical agent, but recent state and local procurement activity under this code does not reflect pharmaceutical purchasing in the traditional sense. Instead, Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services — a contract encompassing laboratory staffing, specimen handling, immunoassay screening with confirmatory testing (LC/MS/MS or GC/MS), and ancillary testing methodologies including oral fluid and hair analysis. The scope includes operation of two collection sites in the Plano and McKinney area with specified hours and staffing, plus an Interactive Voice Response system for randomized testing notifications and electronic result reporting. This appears to be a case of code assignment misalignment; the solicitation is fundamentally a drug-testing services contract rather than a purchase of vetrabutine itself, and vetrabutine does not appear in the RFP scope.

Collin County, Texas is the sole identified issuing body in the recent opportunities block, with an estimated contract value of $600,000 and a term of two years commencing September 1, 2026, plus three optional one-year renewal periods not to exceed five years total. The RFP due date was July 23, 2026 at 2:00 p.m., with an anticipated award date of August 10, 2026. Evaluation comprises compliance review and detailed proposal assessment on vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional Phase 2 demonstrations and interviews (up to 30 points). Pricing is submitted on a per-test basis with three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives); annual testing demand is approximately 25,031 tests. The successful vendor must maintain lab certification from SAMHSA, TX DPS, or CAP. The code shows minimal recent relevant activity; broader drug-testing procurement under state and local corrections or probation departments typically aligns with different UNSPSC families focused on laboratory and testing services rather than a specific pharmaceutical commodity.